Shoulder Innovations, Inc. (SI) AI Stock Analysis

• Market Cap: $315.62M
• Dividend Yield: N/A
• Average Volume (3M): 130.13K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.01
• Revenue Growth: 39.97%
• EPS Growth: -148.57%
• Country: US
• Employees: 300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Specialties
• EPS (TTM): -0.64
• Shares Outstanding: 20,601,685
• 10 Day Avg. Volume: 53,279
• 30 Day Avg. Volume: 130,135
• PEG Ratio: -0.88
• Price to Book (P/B): 15.39
• Price to Sales (P/S): 9.63
• P/FCF Ratio: -16.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $21.67
• Price Target Upside: 41.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $15.50 ▲(1.17% Upside)

The overall stock score is primarily influenced by financial performance challenges, including profitability and cash flow issues. However, positive technical indicators and a strategic partnership provide some optimism. The valuation remains a concern due to negative earnings, but the corporate event could improve future prospects.

Positive Factors

Strategic Partnership

The partnership to introduce a robotic platform for shoulder arthroplasty enhances SI's market position and operational efficiency, addressing surgical precision and workflow challenges.

Revenue Growth

Consistent revenue growth indicates strong market demand and successful product adoption, supporting long-term business expansion and stability.

Innovative Product Development

Developing innovative solutions like the micro-robotic system positions SI as a leader in orthopedic technology, potentially capturing more market share.

Negative Factors

Profitability Challenges

Ongoing profitability issues may hinder financial health and limit reinvestment capacity, affecting long-term growth and competitive positioning.

High Operating Losses

Sustained high operating losses can strain resources, necessitating strategic adjustments to improve cost management and operational efficiency.

Increased Leverage

Higher leverage increases financial risk, potentially impacting cash flow and limiting strategic flexibility if not managed carefully.

Shoulder Innovations, Inc. Business Overview & Revenue Model

Company Description

Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.

How the Company Makes Money

Shoulder Innovations, Inc. generates revenue primarily through the sale of its orthopedic surgical products, including implants and instruments used in shoulder surgeries. The company utilizes a direct sales model, partnering with hospitals, surgical centers, and orthopedic surgeons to provide its products. Additionally, SI may engage in strategic partnerships with larger medical device companies to expand its distribution channels and market reach. Revenue is also supplemented through training programs for surgical staff and ongoing support services, ensuring that healthcare providers are well equipped to use SI's products effectively.

Shoulder Innovations, Inc. Financial Statement Overview

Summary

Shoulder Innovations, Inc. is experiencing revenue growth, but profitability and cash flow challenges persist. The company needs to address its high operating losses and improve cash flow management to enhance financial stability. The balance sheet shows increased leverage, which could be a risk if not carefully managed.

Income Statement

Shoulder Innovations, Inc. shows a significant increase in revenue from the previous year, indicating growth potential. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains strong, but the high operating losses are concerning.

Balance Sheet

The company's debt-to-equity ratio has increased, suggesting a rise in leverage, which could pose a risk if not managed properly. The return on equity is negative, reflecting ongoing losses. However, the equity ratio indicates a reasonable level of equity financing relative to total assets.

Cash Flow

Cash flow from operations is negative, which is a concern for liquidity. The free cash flow to net income ratio is positive, indicating that the company is generating cash relative to its net losses, but the overall cash flow position is weak.

Breakdown	TTM	Dec 2024	Dec 2023
Income Statement
Total Revenue	32.90M	31.62M	19.27M
Gross Profit	25.14M	24.34M	15.27M
EBITDA	-29.70M	-12.11M	-10.25M
Net Income	-32.59M	-15.62M	-12.65M
Balance Sheet
Total Assets	177.76M	43.08M	54.29M
Cash, Cash Equivalents and Short-Term Investments	137.29M	15.04M	32.81M
Total Debt	14.92M	14.73M	14.46M
Total Liabilities	14.91M	97.78M	94.03M
Stockholders Equity	162.85M	19.78M	34.74M
Cash Flow
Free Cash Flow	-24.95M	-18.16M	-15.89M
Operating Cash Flow	-19.83M	-14.14M	-13.14M
Investing Cash Flow	-78.31M	13.96M	-28.97M
Financing Cash Flow	146.96M	66.00K	44.73M

Shoulder Innovations, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	75 Outperform	$1.93B	36.56	15.02%	0.94%	13.07%	27.98%
VCEL	71 Outperform	$1.82B	149.71	4.52%	―	14.05%	241.86%
MMSI	68 Neutral	$5.20B	44.89	8.30%	―	11.49%	-2.89%
ICUI	61 Neutral	$3.58B	-466.87	-0.35%	―	-0.81%	93.27%
ATEC	57 Neutral	$2.97B	―	-540.40%	―	27.11%	17.66%
SI	55 Neutral	$315.62M	-8.55	―	―	39.97%	-148.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Shoulder Innovations, Inc. Corporate Events

Shoulder Innovations Partners with Interventional Systems

On December 3, 2025, Shoulder Innovations, Inc. announced a strategic partnership with Interventional Systems to introduce a robotic platform for shoulder arthroplasty. This collaboration aims to enhance surgical precision and efficiency, particularly benefiting ambulatory surgery centers by providing a portable solution that addresses challenges like high costs and technical learning curves. The partnership is expected to improve the company’s market position by leveraging Interventional Systems’ proven micro-robotic technology, potentially transforming operating rooms into robotic environments.